Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Composite outcome of CKD progression: defined as doubling of serum creatinine during follow up (mean serum creatinine during follow up divided by mean serum creatinine at index date 2) or incident stage 5 CKD during follow up period
Findings from two related phase 2 clinical trials looking at the novel triple-hormone receptor agonist retatrutide were presented during a late-breaking symposium at the 83rd Scientific Sessions
- Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Fitzgerald GA and Patrono C.The coxibs, selective inhibitors of cyclooxygenase-2
Jastreboff AM , Aronne LJ , Ahmad NN , et al
US$ 22.66
US$ 28.31
US$ 29.70
